Clinical study of Shugan Jianpi Huazhi Decoction combined with Tongluo Yanggan application in the treatment of non-alcoholic fatty liver disease

Efficacy evaluation and mechanism study of Yiqi Huashi and Jiedu Tongluo methods in chronic liver disease

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2022000098

Enrollment

Unknown

Registered

2022-06-24

Start date

2022-09-26

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

Treatment group:Shugan Jianpi Huazhi Decoction combined with Tongluo Yanggan application

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of non-alcoholic fatty liver disease; 2. Meet the diagnostic criteria of Tanzhuo Neizu; 3. Between the ages of 18 and 65, regardless of gender; 4. Willing to participate in the research and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with hepatitis B, C and other liver diseases; 2. Patients with alcoholic liver disease, autoimmune liver disease, drug liver disease, toxic hepatitis, hepatic malignant tumor, occult hepatitis, liver disease of unknown cause; 3. Pregnant or lactation women, allergic constitution; 4. Patients with mental abnormalities who cannot cooperate with this study; 5. Patients complicated with serious diseases of the heart, brain, lung, kidney, hematopoietic and immune systems; 6. Other conditions considered unsuitable for inclusion by the researcher.

Design outcomes

Primary

Measure	Time frame
blood uric acid;liver ultrasound;LSM;blood sugar;liver function;lipid profile;CAP;	—

Secondary

Measure	Time frame
FIB-4 Index;Four items of liver fibrosis;TCM symptoms;APRI Index;	—

Countries

China

Contacts

Public Contactlvwenliang

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

lvwenliang@sohu.com18601237779

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026